Eli Lilly plans to launch its diabetes and weight loss medication in the main emerging markets, such as Mexico, India and Brazil in the second semester of 2025, as the production capacity increases, its financial president said Monday.
The world demand for diabetes medicines and Lilly’s weight loss and his Danish rival Novo Nordisk has been extraordinary. The new launches have a great market opportunity, since it is some of the most populated countries and with raising obesity rates.
“We are talking about 900 million patients who could benefit from Mounjaro,” said Lucas Montece, financial president, investors and analysts at the World Health Conference of Readink Partners.
Lee: world population with obesity will grow 115% between 2010 and 2030: study
“We plan to launch in new countries (…) what we call large emerging market countries, which will boost significant growth in the last part of the year, but also more around 2026.”
In February last year, executive president David Ricks had told Reuters that Lilly hoped to launch Mounjaro in India in 2025.
Mounjaro, chemically known as Tirzepatida, is currently sold in the United Kingdom and Europe under the same brand for both diabetes and weight loss. However, in the United States it is sold as Zepbound for obesity.
Lilly’s drug had a limited launch in China last year, but the company expects a major in 2025. Its Danish rival Novo Nordisk launched its popular Wegovy obesity medicine in China in November last year.
Lee: cannabis and weight loss: A new tool against obesity in Mexico?
“We continue to plan new launches as we increase production,” said Montice.
With Reuters information
Do you like to inform yourself for Google News? Follow our showcase to have the best stories
